Mesothelioma.com Resources for Patients and their Families

Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy

Brief Summary

The doctors are testing a Wilms Tumor-1 (WT1) vaccine to see if it delays or prevents the mesothelioma from growing back after surgery. WT1 is a protein in cancer cells that regulates gene expression and causes cell growth. Mesothelioma tumors generally have high levels of WT1.This study was originally designed to have two treatment groups. One group received non-specific immunotherapy with medications called Montanide and Sargramostim (Granulocyte Macrophage Colony Stimulating Factor, GM-CSF). Enrollment to this group has stopped The other group, which continues receives more specific immunotherapy with the WT1 vaccine plus Montanide and GM-CSF. Both Montanide and GM-CSF are commonly given along with vaccines because they have a general effect in boosting the immune response. Some researchers believe that this general increase in the immune system may have some effect in treating cancer. Some studies using GM-CSF with melanoma vaccines have suggested that it could lessen the effects of the vaccine. The addition of the WT1 proteins makes this therapy more directed to mesothelioma. The combination of WT1 vaccine with Montanide and GM-CSF has been tested in a prior trial including 9 patients with advanced mesothelioma. In that trial, the vaccine was safe and caused an immune response.

Tracking Information
First Received DateDecember 21, 2010
Last Changed DateJanuary 4, 2017
Start DateDecember 2010
Anticipated Primary Completion DateDecember 2017
Primary Outcome Measures

To assess the 1-year progression free survival in patients [Time Frame: 1 year]

Secondary Outcome Measures

To confirm the immunogenicity of the WT-1 analog peptide vaccine [Time Frame: 1 year]

To assess the utility of using the serum marker [Time Frame: 1 year]

overall survival [Time Frame: 1 year]

Descriptive Information
PhasePhase 2
Study TypeInterventional
Condition
  • Malignant Pleural Mesothelioma
Intervention
  • Biological: WT-1-vaccine Montanide + GM-CSF
  • Biological: Montanide adjuvant + GM-CSF (This arm is closed)
Study Arms / Comparison Groups2 / 0
Recruitment Information
Recruitment StatusActive, not recruiting
Actual Enrollment31
GenderAll
Ages18 Years - N/A
Accepts Healthy VolunteersNo
Eligibility Criteria

Inclusion Criteria:

- Pathologic diagnosis of malignant pleural mesothelioma (MPM) confirmed at participating institution.

- Positive immunohistochemical staining for WT-1 (greater than 10% of cells).

- Completion of multimodality therapy. This must include surgical resection by either pleurectomy/decortication or extrapleural pneumonectomy. The surgery should be performed with the intent of complete resection, though patients with an R1 resection will still be eligible. Patients should have also received treatment with chemotherapy and/or radiation. Patients with an R2 resection are also eligible as long as the site of residual disease is treated post-operatively with radiotherapy.

- 4-12 weeks since completion of combined modality therapy.

- Age > or = to 18 years

- Karnofsky performance status > or = to 70%

- Hematologic parameters: Absolute neutrophil count > or = to 1000/mcL, Platelets > or = to 50K/mcL.

- Biochemical parameters: Total bilirubin < or = to 2.0 mg/dl, AST and ALT < or = to 2.5 x upper limits of normal, Creatinine < or = to 2.0 mg/dl.

Exclusion Criteria:

- Pregnant or lactating women.

- Patients with active infection requiring systemic antibiotics, antiviral, or antifungal treatments.

- Patients with a serious unstable medical illness or another active cancer.

- Patients taking systemic corticosteroids.

- Patients with an immunodeficiency syndrome.

Administrative Information
NCTIDNCT01265433
Responsible Party,
SponsorMemorial Sloan Kettering Cancer Center
Verification DateJanuary 2017
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog

FEATURED CONTENT:


RECENT POSTS:

Remembering Mesothelioma Victims in the UK

The Challenges of Research in Immunotherapy

The Importance of Cancer Research in Immunotherapy

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: